AI-Powered Research

General:
Subjects who want to participate in the study should be over 18 years of age and be able to give informed consent.;Patients with coronary artery disease:
These patients should have proven coronary artery disease, defined as >=50% diameter stenosis objectified by coronary angiography. ;Patients with suspected small vessel disease:
These patients should have a positive exercise ECG but no evidence of significant coronary artery disease on their coronary angiogram. ;The time between the coronary angiogram and the MR perfusion scan and OPS imaging cannot exceed one year. It can be reasonably expected that the status of the coronaries will not have changed significantly over this time period if the symptoms of angina have not changed. ;Healthy controls:
These subjects must be free of angina pectoris or (a history of) coronary artery disease.

Exclusion Criteria

Patients:;General:
- Age < 18 years.
- Unable to give informed consent.;Other cardiac pathology:
- Atrial fibrillation.
- Unstable angina pectoris (persistent CCS class IV despite medical treatment).
- Cardiogenic shock.
- Congestive heart failure NYHA class >=III. ;Contraindication to adenosine side effects:
- AV-block (2nd or 3rd degree).
- Severe asthma.
- COPD Gold IV.;General contra-indications to MR imaging
- Non compatible metallic implant (vascular clip, neuro-stimulator, cochlear implant).
- Pacemaker or ICD.
- Claustrophobia.
- Body weight >130 kg.
Contraindication to MRI contrast agent:
- Renal failure (GFR <= 30 mL/min) / chronic kidney disease stage 4 & 5. ;Healthy controls:;General:
- Age < 18 years.
- Unable to give informed consent.;Evidence of coronary artery disease:
- Angina pectoris.
- >=50% diameter coronary stenosis objectified by coronary angiography or computed tomographic (CT) angiography.
- Previous myocardial infarction.
- Previous coronary revascularization.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- MR perfusion imaging during resting conditions and adenosine infusion in a)<br /><br>patients with proven coronary artery disease and b) patient with angina<br /><br>pectoris but without significant coronary artery lesions.<br /><br>- OPS imaging of the sublingual circulation to measure glycocalyx dimension and<br /><br>barrier function before and after sublingual NTG administration in a) patients<br /><br>with proven coronary artery disease, b) patient with angina pectoris but<br /><br>without significant coronary artery lesions, and c) healthy controls.<br /><br></p><br>

Secondary Outcome Measures